PL373788A1 - Nowe krystaliczne postaci gatifloksacyny - Google Patents

Nowe krystaliczne postaci gatifloksacyny

Info

Publication number
PL373788A1
PL373788A1 PL03373788A PL37378803A PL373788A1 PL 373788 A1 PL373788 A1 PL 373788A1 PL 03373788 A PL03373788 A PL 03373788A PL 37378803 A PL37378803 A PL 37378803A PL 373788 A1 PL373788 A1 PL 373788A1
Authority
PL
Poland
Prior art keywords
gatifloxacin
crystalline forms
novel crystalline
novel
forms
Prior art date
Application number
PL03373788A
Other languages
English (en)
Inventor
Valerie Niddam-Hildesheim
Shlomit Wizel
Greta Sterimbaum
Ehud Amir
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Priority claimed from US10/735,029 external-priority patent/US7301024B2/en
Publication of PL373788A1 publication Critical patent/PL373788A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL03373788A 2002-05-10 2003-05-12 Nowe krystaliczne postaci gatifloksacyny PL373788A1 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US37951002P 2002-05-10 2002-05-10
US38909302P 2002-06-14 2002-06-14
US40167202P 2002-08-06 2002-08-06
US40274902P 2002-08-12 2002-08-12
US40986002P 2002-09-10 2002-09-10
US42333802P 2002-11-01 2002-11-01
US43296102P 2002-12-12 2002-12-12
US44481203P 2003-02-03 2003-02-03
US44806203P 2003-02-15 2003-02-15
US10/735,029 US7301024B2 (en) 2002-12-12 2003-12-12 Crystalline forms of gatifloxacin and processes for preparation

Publications (1)

Publication Number Publication Date
PL373788A1 true PL373788A1 (pl) 2005-09-19

Family

ID=37772994

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373788A PL373788A1 (pl) 2002-05-10 2003-05-12 Nowe krystaliczne postaci gatifloksacyny

Country Status (10)

Country Link
US (6) US20060258676A1 (pl)
EP (1) EP1503762A2 (pl)
JP (1) JP2005534633A (pl)
KR (1) KR20040106518A (pl)
CN (1) CN1665504A (pl)
AU (1) AU2003232113A1 (pl)
CA (1) CA2485262A1 (pl)
IL (1) IL165115A0 (pl)
PL (1) PL373788A1 (pl)
WO (1) WO2003094919A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511618A (ja) * 2002-12-12 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの結晶形態および調製の方法
AU2003304118A1 (en) * 2003-05-19 2004-12-03 Hetero Drugs Limited Purification methods of gatifloxacin and a novel form of gatifloxacin
ES2232310B1 (es) * 2003-11-13 2006-08-01 Quimica Sintetica, S.A. Formula cristalina no higroscopica de gatifloxacino.
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
WO2005118546A1 (en) * 2004-06-04 2005-12-15 Matrix Laboratories Ltd Novel crystalline forms of gatifloxacin
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
US7943782B2 (en) * 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
KR100228572B1 (ko) * 1992-01-31 1999-11-01 이병언 퀴놀론카르복실산 유도체 수화물 결정
JP3449658B2 (ja) * 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
JP2006516152A (ja) * 2002-08-14 2006-06-22 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの合成
JP2006511618A (ja) * 2002-12-12 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの結晶形態および調製の方法

Also Published As

Publication number Publication date
US20060258675A1 (en) 2006-11-16
JP2005534633A (ja) 2005-11-17
EP1503762A2 (en) 2005-02-09
US20060258674A1 (en) 2006-11-16
CA2485262A1 (en) 2003-11-20
AU2003232113A1 (en) 2003-11-11
IL165115A0 (en) 2005-12-18
KR20040106518A (ko) 2004-12-17
US20060252770A1 (en) 2006-11-09
US20060258676A1 (en) 2006-11-16
WO2003094919A3 (en) 2004-03-18
US20060252771A1 (en) 2006-11-09
CN1665504A (zh) 2005-09-07
WO2003094919A2 (en) 2003-11-20
US20060252772A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
AU2003230192A1 (en) Novel crystalline forms of aripiprazole
ZA200409981B (en) Novel formate salt of O-desmethyl-venlafaxine
HK1103294A1 (en) Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride (6r)-l--
ZA200507344B (en) Novel crystalline modification of the anhydrate of boscalid
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
IL166592A0 (en) Novel crystalline forms of gatifloxacin
IL165115A0 (en) Novel crystalline forms of gatifloxacin
AU2003245029A1 (en) Novel crystalline forms of donepezil hydrochloride
AU2003245027A1 (en) Novel crystalline forms of ziprasidone hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
IL165690A0 (en) Novel crystalline forms of gatifloxacin
IL174969A0 (en) Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL375437A1 (pl) Synteza gatifloksacyny
AU2003300874A1 (en) Crystalline forms of gatifloxacin and processes for preparation
AU2003217437A1 (en) Novel crystalline forms of lamotrigine
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003230194A1 (en) Novel crystalline forms of gatifloxacin
IL174063A0 (en) Crystalline form of gatifloxacin
AU2003238668A1 (en) Novel crystalline forms of valdecoxib
AU2003209670A1 (en) Novel crystalline forms of trandolapril
GB0228533D0 (en) Crystalline form
AU2003217439A1 (en) Novel crystalline forms of finasteride

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)